Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for tumor antigen testing by immunoassay — specifically CA 15-3 and CA 27.29 — effective May 15, 2026. Here's what billing teams need to do before that date.
CMS CA 15-3/CA 27.29 tumor antigen coverage policy governs when Medicare pays for these serum markers in breast cancer monitoring. This policy does not carry a numbered policy code in the CMS system. The policy document lists no specific CPT or HCPCS codes — we note that gap directly below. Billing teams should treat this as a signal to verify applicable codes against your MAC's local coverage determination before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Tumor Antigen by Immunoassay — CA 15-3/CA 27.29 |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, hematology/oncology, internal medicine, laboratory billing |
| Key Action | Audit your CA 15-3 and CA 27.29 claims for medical necessity documentation before May 15, 2026 |
CMS CA 15-3 and CA 27.29 Coverage Criteria and Medical Necessity Requirements 2026
The CMS CA 15-3/CA 27.29 tumor antigen coverage policy governs Medicare reimbursement for two serum tumor markers used primarily to monitor breast cancer treatment response. CA 15-3 and CA 27.29 are not interchangeable in clinical documentation — they measure related but distinct antigens, and your documentation needs to reflect which marker was ordered and why.
Medicare's medical necessity standard for these markers has always been strict. These tests are not covered for breast cancer screening or initial diagnosis. Coverage applies to monitoring of patients with known, established breast cancer — specifically those with documented metastatic or advanced disease where the marker result will inform treatment decisions.
The real risk here is the gap between how oncologists order these tests and how your billing team documents the indication. A physician ordering CA 27.29 to "follow the patient" is not the same as documented medical necessity for monitoring response to therapy in a patient with stage IV breast cancer. That distinction is what drives claim denial on these codes.
Prior authorization is not typically required for these markers under traditional Medicare. But your MAC may have issued a local coverage determination that adds requirements beyond the national policy. Check your MAC's LCD before May 15, 2026 — this modified policy may prompt MAC-level updates that follow the national change.
CMS CA 15-3 and CA 27.29 Exclusions and Non-Covered Indications
CMS does not cover CA 15-3 or CA 27.29 for breast cancer screening in asymptomatic patients. That's not a nuance — it's a hard exclusion. If a patient has no prior breast cancer diagnosis, these tests don't meet medical necessity under Medicare's coverage policy.
Routine surveillance in early-stage breast cancer patients who have completed treatment and show no evidence of disease is also a common denial trigger. CMS has historically viewed serial tumor marker testing in this population as not medically necessary. Your medical director and oncology team need to align on this before claims go out the door.
Testing performed solely to reassure a patient — or ordered as part of a broad panel without a specific clinical question tied to active treatment — falls outside covered indications. Documentation that says "patient requests" or "routine follow-up" without clinical context will not hold up on review.
Coverage Indications at a Glance
The published policy document does not provide a detailed, indication-by-indication breakdown with specific codes. The table below reflects standard CMS medical necessity criteria for CA 15-3 and CA 27.29 based on the governing policy. Talk to your compliance officer if your patient mix includes edge cases not listed here.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Monitoring treatment response in metastatic breast cancer | Covered | Codes not listed in policy document | Must document active treatment and clinical rationale |
| Monitoring for recurrence in high-risk breast cancer patients with clinical signs | Covered (with documentation) | Codes not listed in policy document | Requires documented clinical suspicion, not routine surveillance |
| Initial diagnosis of breast cancer | Not Covered | N/A | Not a diagnostic marker under CMS policy |
| Breast cancer screening in asymptomatic patients | Not Covered | N/A | Hard exclusion — no clinical scenario changes this |
| Routine surveillance, no evidence of disease, completed treatment | Not Covered | N/A | Serial testing without active treatment indication denied |
| CA 15-3 and CA 27.29 ordered simultaneously | Not Covered | N/A | Duplicative — CMS does not cover both markers on the same date of service |
That last row matters. Ordering CA 15-3 and CA 27.29 on the same date is a common billing mistake. They measure overlapping antigens. CMS treats simultaneous ordering as duplicative and will deny one of the two. Pick one marker per encounter and document the rationale.
CMS CA 15-3 and CA 27.29 Billing Guidelines and Action Items 2026
This modification is effective May 15, 2026. That gives your team time to act — but not much. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Audit your open and pending claims for CA 15-3 and CA 27.29 testing billed to Medicare. Pull claims from the last 12 months. Look for patterns: simultaneous billing of both markers on the same date, routine surveillance claims, and any claims where the diagnosis code doesn't clearly indicate active or metastatic breast cancer. |
| 2 | Review your charge capture process before May 15, 2026. If your oncology or lab team is ordering both CA 15-3 and CA 27.29 on the same encounter, your charge capture should flag that as a duplicate. Set up an edit or review step that catches simultaneous orders before the claim drops. |
| 3 | Update your medical necessity documentation templates. Work with your medical director to build order-entry templates that capture the specific clinical question being answered — stage of disease, current treatment regimen, and how the result will change management. "Monitor patient" is not sufficient. "Monitor CA 27.29 to assess response to current chemotherapy regimen in stage IV breast cancer" is. |
| 4 | Check your MAC's local coverage determination. This national CMS policy modification may prompt your Medicare Administrative Contractor to update or reissue their LCD for tumor antigen testing. Search your MAC's website for any LCD governing tumor marker immunoassays. If an updated LCD drops between now and May 15, your billing guidelines may need to shift again. |
| 5 | Train your front-end billing staff on the covered indications table above. Claim denial on these markers often starts with a weak diagnosis code on the order — not with the lab itself. Your billing team needs to reject orders that arrive without a qualifying ICD-10 before the claim is ever submitted. |
| 6 | Talk to your compliance officer if you operate high-volume oncology labs or infusion centers. This policy affects reimbursement across a broad patient population. If CA 15-3 or CA 27.29 testing represents meaningful revenue, a compliance review before May 15 is worth the time. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for CA 15-3/CA 27.29 Under This CMS Policy
Important: The policy document for this CMS modification does not list specific CPT, HCPCS, or ICD-10 codes. We do not fabricate codes. What follows is what you need to do instead.
Contact your MAC directly and request the applicable CPT codes covered under their LCD for tumor antigen immunoassay testing. The commonly referenced lab codes for CA 15-3 and CA 27.29 are well-established in the CPT code set — but because this specific policy document does not enumerate them, your billing team should verify against the official CMS or MAC source before billing under this modified coverage policy.
Do not rely on prior-year fee schedule data or third-party code lookups as your compliance foundation. Pull the codes directly from the policy source or your MAC's published LCD. That documentation protects you on audit.
If codes are added to this policy in a subsequent version, PayerPolicy will update this post and flag the change in your policy alerts dashboard.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.